Serum Macrophage Migration Inhibitory Factor As a Biomarker of Active Pulmonary Tuberculosis

Overview

Journal Ann Lab Med

Specialty Pathology

Date 2017 Oct 27

PMID 29071813

Citations 3

Authors

Zhong Bo Shang

Jun Wang

Shou Gang Kuai

Yin Yin Zhang

Qin Fang Ou

Hao Pei

Li Hua Huang

Affiliations

Soon will be listed here.

Abstract

Background: Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine with chemokine-like functions, has been shown to play a central role in several acute and chronic inflammatory diseases. However, limited information is available regarding the use of MIF as an inflammatory pathway marker in patients with tuberculosis. This study aimed to investigate the association of MIF with IFN-γ and TNF-α in active pulmonary tuberculosis (APTB) following anti-tuberculosis treatment.

Methods: The MIF, TNF-α, and IFN-γ serum levels were determined in 47 patients with APTB by cytokine-specific ELISA at four phases: prior to anti-tuberculosis drug treatment (baseline), and following 2, 4, and 6 months of treatment. In addition, we measured the MIF, TNF-α, and IFN-γ serum levels in 50 health controls.

Results: MIF serum levels were significantly elevated (P<0.05) in patients with APTB prior to treatment compared with that in control subjects, and TNF-α ≥449.7 pg/mL was associated with high MIF levels (≥13.1 ng/mL). MIF levels were significantly reduced (P<0.01) following 2, 4, and 6 months of treatment, with variations in TNF-α and IFN-γ serum levels. MIF levels were positively correlated with the paired TNF-α level at baseline (r=0.1103, P=0.0316) and following 6 months of treatment (r=0.09569, P=0.0364).

Conclusions: A reduction in the MIF serum levels in patients with APTB following anti-tuberculosis treatment may positively affect host immune protection against Mycobacterium tuberculosis infection. Thus, serum MIF levels may constitute a useful marker for assessing therapy effectiveness in patients with APTB.

Citing Articles

The Role of Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (D-DT/MIF-2) in Infections: A Clinical Perspective.

Breidung D, Megas I, Freytag D, Bernhagen J, Grieb G Biomedicines. 2024; 12(1).

PMID: 38275363 PMC: 10813530. DOI: 10.3390/biomedicines12010002.

Genetic Variants of the Gene and Susceptibility of Rectal Cancer.

Chuo D, Lin D, Yin M, Chen Y Pharmgenomics Pers Med. 2021; 14:55-60.

PMID: 33469341 PMC: 7812028. DOI: 10.2147/PGPM.S282653.

Prognostic value of serum macrophage migration inhibitory factor levels in pulmonary tuberculosis.

Wang Q, Han W, Niu J, Sun B, Dong W, Li G Respir Res. 2019; 20(1):50.

PMID: 30841876 PMC: 6402089. DOI: 10.1186/s12931-019-1004-3.

References

Chakravarty S, Zhu G, Tsai M, Mohan V, Marino S, Kirschner D . Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun. 2008; 76(3):916-26. PMC: 2258824. DOI: 10.1128/IAI.01011-07. View

Yende S, Angus D, Kong L, Kellum J, Weissfeld L, Ferrell R . The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J. 2009; 23(8):2403-11. PMC: 2717777. DOI: 10.1096/fj.09-129445. View

Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T . An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010; 466(7309):973-7. PMC: 3492754. DOI: 10.1038/nature09247. View

van Crevel R, Ottenhoff T, van der Meer J . Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002; 15(2):294-309. PMC: 118070. DOI: 10.1128/CMR.15.2.294-309.2002. View

Cooper A, Khader S . The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev. 2009; 226:191-204. PMC: 4298252. DOI: 10.1111/j.1600-065X.2008.00702.x. View

Ameglio F, Casarini M, Capoluongo E, Mattia P, Puglisi G, Giosue S . Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. Int J Tuberc Lung Dis. 2005; 9(1):98-104. View

Santos L, Morand E . Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta. 2008; 399(1-2):1-7. DOI: 10.1016/j.cca.2008.09.014. View

Gutierrez M, Master S, Singh S, Taylor G, Colombo M, Deretic V . Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004; 119(6):753-66. DOI: 10.1016/j.cell.2004.11.038. View

Sharma S, Sharma M, Roy S, Kumar P, Bose M . Mycobacterium tuberculosis induces high production of nitric oxide in coordination with production of tumour necrosis factor-alpha in patients with fresh active tuberculosis but not in MDR tuberculosis. Immunol Cell Biol. 2004; 82(4):377-82. DOI: 10.1111/j.0818-9641.2004.01245.x. View

10.

Renner P, Roger T, Bochud P, Sprong T, Sweep F, Bochud M . A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J. 2011; 26(2):907-16. DOI: 10.1096/fj.11-195065. View

11.

Leng L, Bucala R . Macrophage migration inhibitory factor. Crit Care Med. 2005; 33(12 Suppl):S475-7. DOI: 10.1097/01.ccm.0000191278.04636.d8. View

12.

Botha T, Ryffel B . Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol. 2003; 171(6):3110-8. DOI: 10.4049/jimmunol.171.6.3110. View

13.

Bean A, Roach D, Briscoe H, France M, Korner H, Sedgwick J . Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999; 162(6):3504-11. View

14.

Boom W, Canaday D, Fulton S, Gehring A, Rojas R, Torres M . Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis (Edinb). 2003; 83(1-3):98-106. DOI: 10.1016/s1472-9792(02)00054-9. View

15.

Morand E, Leech M, Bernhagen J . MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov. 2006; 5(5):399-410. DOI: 10.1038/nrd2029. View

16.

Mohan V, Scanga C, Yu K, Scott H, Tanaka K, Tsang E . Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001; 69(3):1847-55. PMC: 98092. DOI: 10.1128/IAI.69.3.1847-1855.2001. View

17.

Tillmann S, Bernhagen J, Noels H . Arrest Functions of the MIF Ligand/Receptor Axes in Atherogenesis. Front Immunol. 2013; 4:115. PMC: 3655399. DOI: 10.3389/fimmu.2013.00115. View

18.

Lolis E, Bucala R . Macrophage migration inhibitory factor. Expert Opin Ther Targets. 2003; 7(2):153-64. DOI: 10.1517/14728222.7.2.153. View

19.

Awandare G, Martinson J, Were T, Ouma C, Davenport G, Ongecha J . MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. J Infect Dis. 2009; 200(4):629-37. PMC: 3607439. DOI: 10.1086/600894. View

20.

Llamas-Covarrubias M, Valle Y, Bucala R, Navarro-Hernandez R, Palafox-Sanchez C, Padilla-Gutierrez J . Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine. 2013; 61(3):759-65. PMC: 3683988. DOI: 10.1016/j.cyto.2012.12.032. View